JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

National Trends in Pediatric Admissions for Diabetic Ketoacidosis, 2006-2016.

BACKGROUND AND OBJECTIVES: Diabetic ketoacidosis (DKA) rates in the US are rising. Prior studies suggest higher rates in younger populations, but no studies have evaluated national trends in pediatric populations and differences by subgroups. As such, we sought to examine national trends in pediatric DKA.

METHODS: We used the 2006, 2009, 2012, and 2016 Kids' Inpatient Database (KID) to identify pediatric DKA admissions among a nationally-representative sample of admissions youth ≤20 years-old. We estimate DKA admission per 10,000 admissions and per 10,000 population, charges, length of stay (LOS), and trends over time among all hospitalizations and by demographic subgroups. Regression models were used to evaluate differences in DKA rates within subgroups overtime.

RESULTS: Between 2006 and 2016, there were 149,535 admissions for DKA. Unadjusted DKA rate per admission increased from 120.5 (95%CI:115.9-125.2) in 2006 to 217.7 (95%CI:208.3-227.5) in 2016. The mean charge per admission increased from $14,548 (95%CI:$13,971-$15,125) in 2006 to $20,997 (95%CI:$19,973-$22,022) in 2016, while mean LOS decreased from 2.51 (95%CI:2.45-2.57) to 2.28 (95%CI:2.23-2.33) days. Higher DKA rates occurred among 18-20 year-old, females, Black youth, without private insurance, with lower incomes, and from non-urban areas. Young adults, men, those without private insurance, and from non-urban areas had greater increases in DKA rates across time.

CONCLUSIONS: Pediatric DKA admissions have risen by 40% in the US and vulnerable subgroups remain at highest risk. Further studies should characterize the challenges experienced by these groups, to inform interventions to mitigate their DKA risk and to address the rising DKA rates nationally.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app